COMPANY PROFILE / #3148
Eclipse Bioinnovations
San Diego, CAVenture Capital-Backed
OVERVIEW
Developer of cell-free genomics technologies designed to provide specialized genomics-based products and services. The company's technology focuses on increasing crosslinking and immunoprecipitation and assists in identifying ribonucleic acid binding protein targets, enabling scientists and academic customers to accelerate research and develop new and effective drugs to cure a wide range of human diseases.
已融资23.91
最新估值39.91
员工数44
成立年份2017
公司概况
- Companies
- Eclipse Bioinnovations
- Description
- Developer of cell-free genomics technologies designed to provide specialized genomics-based products and services. The company's technology focuses on increasing crosslinking and immunoprecipitation and assists in identifying ribonucleic acid binding protein targets, enabling scientists and academic customers to accelerate research and develop new and effective drugs to cure a wide range of human diseases.
- Website
- eclipsebio.com
- HQ Location
- San Diego, CA
- Year Founded
- 2017
- Keywords
- genomics company, genomics technologies, immunoassay development, immunoassay testing, immuno-oncology, protein identification, rna biology, rna medicine, rna testing tool, sequencing services
- Competitors
- LC Sciences, Paragon Genomics, Oxford Nanopore Technologies, Ambry Genetics, DNAnexus, Pacific BioSciences of California, Swift Biosciences, Fabric Genomics, Pillar Biosciences, Myriad Genetics, Human Longevity, PierianDx, Gene By Gene
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 23.91
- First Financing Date
- 01-Jan-2017
- First Financing Size
- —
- First Financing Valuation
- —
- Last Financing Date
- 01-Jan-2026
- Last Financing Deal Type
- Later Stage VC
- Last Financing Size
- 4.91
- Last Financing Valuation
- 39.91
- Last Financing Status
- Completed
- Last Known Valuation
- 39.91
- Last Known Valuation Date
- 01-Jan-2026
- Last Known Valuation Deal Type
- Later Stage VC
- Valuation Estimate
- 58.08
- Valuation Estimate Growth Rate
- 45.54%
- Active Investors
- Alexandria Venture Investments, Brainstorm Ventures, Economic Development Innovations Singapore, iGlobe Partners, Magnetic Ventures, National Institutes of Health, Phoenix Venture Partners, Robust Evolve, The National Human Genome Research Institute, U.S. Department of Health and Human Services, University of California, San Diego
- # Active Investors
- 11
- Acquirers
- —
团队与联系人
- Employees
- 44
- Employee Growth %
- 10.00%
- Employee History
- 2026: 44, 2025: 40, 2024: 34, 2023: 42, 2022: 42, 2021: 23, 2020: 18
- Primary Contact
- Eugene Yeo
- Primary Contact Title
- Co-Founder & Board Member
- Primary Contact Email
- eyeo@orbitaltx.com
- Primary Contact Phone
- —
增长与经营
- Revenue
- —
- Revenue Growth %
- —
- Growth Rate
- 0.23%
- Growth Rate % Change
- —
- Growth Rate Percentile
- 91
- Size Multiple
- 7.31x
- Size Multiple % Change
- 0.00%
- Size Multiple Change
- 0.00x
- Size Multiple Percentile
- 89
- Majestic Referring Domains
- 237
- SimilarWeb Unique Visitors
- 859
- SimilarWeb Unique Visitors Change
- 121
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- 7%
- Success Probability Over Time – 3 Year
- 21%
- Success Probability Over Time – 5 Year
- 32%
记录来源：public.companies · 原始序号 #3148 · 所有字段均按数据库原值展示。